ClinicalTrials.govpublic full text
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid
myelodysplastic syndromes, thrombocytopenia, revlimid, lenalidomide, low platelet count, low risk myelodysplastic syndrome, intermediate 1 myelodysplastic syndrome, mds, myelodysplastic syndrome, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 801624
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.